We recently compiled a list of the 12 Stocks Under $5 With Biggest Upside Potential. In this article, we are going to take a ...

Mutual Advisors LLC bought a new position in ImmunityBio, Inc. (NASDAQ:IBRX – Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC).

CULVER CITY, Calif., January 29, 2025--ImmunityBio, Inc. (NASDAQ: IBRX) today announced it has entered into a collaboration and supply agreement with BeiGene, Ltd. (to be changed to BeOne ...

ImmunityBio, Inc.'s Anktiva shows promise for solid tumors, with growing sales and financing boosting growth potential. Click ...

We recently compiled a list of the 10 Firms Shine Amid Wall Street’s Lackluster Trading. In this article, we are going to ...

ImmunityBio has a promising cancer treatment, Anktiva. We warn of financial risks and lack of transparency for retail investors. See more on IBRX stock here.

ImmunityBio (IBRX) announced the European Medicines Agency has accepted for review and begun assessing the marketing authorization application ...

1 Day IBRX 1.60% DJIA -0.32% S&P Mid Cap 400 -0.08% Health Care/Life Sciences -0.52% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

CULVER CITY, Calif., January 27, 2025--ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced the European Medicines Agency (EMA) has accepted for review and begun ...